These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21141654)

  • 1. Switching and combining antipsychotics.
    Correll CU
    CNS Spectr; 2010 Apr; 15(4 Suppl 6):8-11. PubMed ID: 21141654
    [No Abstract]   [Full Text] [Related]  

  • 2. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
    Thone J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):481-2. PubMed ID: 18070865
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 7. Aripirazole-olanzapine combination for treatment of schizophrenia.
    Duggal HS
    Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
    [No Abstract]   [Full Text] [Related]  

  • 8. Supersensitivity psychosis after tapering aripiprazole: a case report.
    Chang CC; Hsu WY; Chen SH
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):388-9. PubMed ID: 19166895
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
    Deng C; Chen J; Hu C; Huang XF
    J Clin Psychopharmacol; 2010 Aug; 30(4):480-1. PubMed ID: 20631576
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
    Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
    J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
    Schuster JP; Raucher-Chéné D; Lemogne C; Rouillon F; Gasquet I; Leguay D; Gierski F; Azorin JM; Limosin F
    J Clin Psychopharmacol; 2012 Oct; 32(5):672-7. PubMed ID: 22926602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics: special formulations for acute agitation.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2005 Oct; 43(10):14-7. PubMed ID: 16294833
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching antipsychotic medications: not enough, too often, or just right?
    Weiden PJ
    Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
    [No Abstract]   [Full Text] [Related]  

  • 15. Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.
    Luebbe G; Kropp S; Harms E; Ziegenbein M
    Pharmacopsychiatry; 2006 Mar; 39(2):76. PubMed ID: 16555168
    [No Abstract]   [Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
    Kishi T; Moriwaki M; Kitajima T; Kawashima K; Okochi T; Fukuo Y; Furukawa O; Naitoh H; Fujita K; Iwata N
    Psychopharmacology (Berl); 2010 Apr; 209(2):185-90. PubMed ID: 20177883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
    Karunakaran K; Tungaraza TE; Harborne GC
    J Psychopharmacol; 2007 Jun; 21(4):453-6. PubMed ID: 17050662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
    Lerond J; Lothe A; Ryvlin P; Bouvard S; d'Amato T; Ciumas C; Daléry J; Poulet E; Saoud M
    J Clin Psychopharmacol; 2013 Feb; 33(1):84-9. PubMed ID: 23277246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
    Oulis P; Mourikis I; Konstantakopoulos G; Papageorgiou SG; Kouzoupis AV
    J Neuropsychiatry Clin Neurosci; 2010; 22(3):352c.e4-352.e5. PubMed ID: 20686147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.